Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Juan Alberto Guevara Salazar, Jessica Rubí Morán Díaz, Enrique Ramírez Segura & José Guadalupe Trujillo Ferrara. (2021) What are the origins of growing microbial resistance? Both Lamarck and Darwin were right. Expert Review of Anti-infective Therapy 19:5, pages 563-569.
Read now
Read now
Sabine Bélard, Charlotte C Heuvelings, Saskia Janssen & Martin P Grobusch. (2015) Bedaquiline for the treatment of drug-resistant tuberculosis. Expert Review of Anti-infective Therapy 13:5, pages 535-553.
Read now
Read now
Articles from other publishers (29)
Junli Huang & Jianjun Chen. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
227
256
.
Zafran Khan, Daniya Ualiyeva, Ubaid Ahmad & Buhari Yusuf. (2022) Immuno-modulatory drugs: A rapid way to combat the tuberculosis. Medicine in Omics 5-6, pages 100016.
Crossref
Crossref
Michele Mondoni, Laura Saderi & Giovanni Sotgiu. (2021) Novel treatments in multidrug-resistant tuberculosis. Current Opinion in Pharmacology 59, pages 103-115.
Crossref
Crossref
Frank E. A. Hayford, Mumin Ozturk, Robin C. Dolman, Renee Blaauw, Arista Nienaber, Du Toit Loots, Frank Brombacher, Cornelius M. Smuts, Suraj P. Parihar & Linda Malan. (2021) Longer-Term Omega-3 LCPUFA More Effective Adjunct Therapy for Tuberculosis Than Ibuprofen in a C3HeB/FeJ Tuberculosis Mouse Model. Frontiers in Immunology 12.
Crossref
Crossref
Harun Patel, Iqrar Ahmad, Harsha Jadhav, Rahul Pawara, Anand Mundada, Matin Shaikh & Sanjay Surana. (2021) Extensively Drug-resistant Tuberculosis (XDR-TB)-inhibitors to Overcome the Scourge of Drug-resistant Tuberculosis: a Perspective. Reviews and Advances in Chemistry 10:3-4, pages 112-139.
Crossref
Crossref
Gauri S. Shetye, Scott G. Franzblau & Sanghyun Cho. (2020) New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Translational Research 220, pages 68-97.
Crossref
Crossref
Sandeep kumar Marvadi, Vagolu Siva Krishna, Goverdhan Surineni, Rudraraju Srilakshmi Reshma, Balasubramanian Sridhar, Dharmarajan Sriram & Srinivas Kantevari. (2020) Synthesis, in vitro, and in vivo (Zebra fish) antitubercular activity of 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides. Bioorganic Chemistry 96, pages 103626.
Crossref
Crossref
Olga Karoutzou, Dimitra Benaki, Ioannis Papanastasiou, Anthony Vocat & Stewart T. Cole. (2019) Synthesis of New Indole and Adamantane Amido Derivatives with Pharmacological Interest. ChemistrySelect 4:29, pages 8727-8730.
Crossref
Crossref
Harun Patel, Harsha Jadhav, Iqrar Ansari, Rahul Pawara & Sanjay Surana. (2019) Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors. European Journal of Medicinal Chemistry 167, pages 1-9.
Crossref
Crossref
Qianqian Fan, Wai-kit Ming, Wai-ying Yip & Joyce H.S. You. (2019) Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. International Journal of Infectious Diseases 78, pages 44-49.
Crossref
Crossref
Marco Pieroni. 2019. Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis. Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis
27
69
.
Diana Machado, Miriam Girardini, Miguel Viveiros & Marco Pieroni. (2018) Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis. Frontiers in Microbiology 9.
Crossref
Crossref
Yongge Liu, Makoto Matsumoto, Hidekaza Ishida, Kinue Ohguro, Masuhiro Yoshitake, Rajesh Gupta, Lawrence Geiter & Jeffrey Hafkin. (2018) Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis 111, pages 20-30.
Crossref
Crossref
Erika Mohr, Jennifer Hughes, Anja Reuter, Laura Trivino Duran, Gabriella Ferlazzo, Johnny Daniels, Virginia De Azevedo, Yulene Kock, Sarah Jane Steele, Amir Shroufi, Serge Ade, Natavan Alikhanova, Guido Benedetti, Jeffrey Edwards, Helen Cox, Jennifer Furin & Petros Isaakidis. (2018) Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. European Respiratory Journal 51:6, pages 1800017.
Crossref
Crossref
Dorota Olender, Justyna Żwawiak & Lucjusz Zaprutko. (2018) Multidirectional Efficacy of Biologically Active Nitro Compounds Included in Medicines. Pharmaceuticals 11:2, pages 54.
Crossref
Crossref
А. G. NАUMOV & А. V. PАVLUNIN. (2018) PERSPECTIVES OF TARGETED CHEMOTHERAPY WITH DELAMANID IN THE TREATMENT REGIMENS OF THOSE WITH MULTIPLE/EXTENSIVE DRUG RESISTANT TUBERCULOSIS. A SUCCESS, CHANCE OR UNCERTAINTY?. TUBERCULOSIS AND LUNG DISEASES 96:11, pages 74-82.
Crossref
Crossref
Andrea Maurizio Cabibbe, Giovanni Sotgiu, Santiago Izco & Giovanni Battista Migliori. (2017)
Genotypic and phenotypic
M. tuberculosis
resistance: guiding clinicians to prescribe the correct regimens
. European Respiratory Journal 50:6, pages 1702292.
Crossref
Crossref
S. Tiberi, L. D’Ambrosio, R. Centis & G.B. Migliori. (2017) Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?. International Journal of Infectious Diseases 65, pages 133-134.
Crossref
Crossref
Elisa Azzali, Diana Machado, Amit Kaushik, Federica Vacondio, Sara Flisi, Clotilde Silvia Cabassi, Gyanu Lamichhane, Miguel Viveiros, Gabriele Costantino & Marco Pieroni. (2017)
Substituted
N
-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery
. Journal of Medicinal Chemistry 60:16, pages 7108-7122.
Crossref
Crossref
Diana A. Aguilar-Ayala, Margo Cnockaert, Emmanuel André, Koen Andries, Jorge A. Gonzalez-Y-Merchand, Peter Vandamme, Juan Carlos Palomino & Anandi Martin. (2017) In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. Journal of Medical Microbiology 66:8, pages 1140-1143.
Crossref
Crossref
Margareth Dalcolmo, Regina Gayoso, Giovanni Sotgiu, Lia D'Ambrosio, Jorge L. Rocha, Liamar Borga, Fatima Fandinho, Jose U. Braga, Vera M.N. Galesi, Draurio Barreira, Denise A. Sanchez, Fernanda Dockhorn, Rosella Centis, Jose A. Caminero & Giovanni B. Migliori. (2017) Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. European Respiratory Journal 49:3, pages 1602445.
Crossref
Crossref
Ivan Solovic, Rosella Centis, Lia D’Ambrosio, Dina Visca & Giovanni Battista Migliori. (2017) World TB Day 2017: Strengthening the fight against TB. La Presse Médicale 46:2, pages e1-e4.
Crossref
Crossref
Amber Arnold, Graham S. Cooke, Onn Min Kon, Martin Dedicoat, Marc Lipman, Angela Loyse, Philip D. Butcher, Irina Chis Ster & Thomas Stephen Harrison. (2017) Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014. Journal of Infection 74:3, pages 260-271.
Crossref
Crossref
Giovanni Migliori, Emanuele Pontali, Giovanni Sotgiu, Rosella Centis, Lia D’Ambrosio, Simon Tiberi, Marina Tadolini & Susanna Esposito. (2017) Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences 18:2, pages 341.
Crossref
Crossref
David Krieger, Nicolas Schönfeld, Silvan Vesenbeckh, Gudrun Bettermann, Torsten Thomas Bauer, Holger Rüssmann & Harald Mauch. (2016)
Is delamanid a potential agent in the treatment of diseases caused by
Mycobacterium avium-intracellulare
?
. European Respiratory Journal 48:6, pages 1803-1804.
Crossref
Crossref
Giorgia Sulis, Rosella Centis, Giovanni Sotgiu, Lia D’Ambrosio, Emanuele Pontali, Antonio Spanevello, Alberto Matteelli, Alimuddin Zumla & Giovanni Battista Migliori. (2016) Recent developments in the diagnosis and management of tuberculosis. npj Primary Care Respiratory Medicine 26:1.
Crossref
Crossref
Marina Tadolini, Rangjung Dolma Lingtsang, Simon Tiberi, Martin Enwerem, Lia D'Ambrosio, Tsetan Dorji Sadutshang, Rosella Centis & Giovanni Battista Migliori. (2016) First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. European Respiratory Journal 48:3, pages 935-938.
Crossref
Crossref
Mario Raviglione & Giorgia Sulis. (2016) Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. Infectious Disease Reports 8:2, pages 6570.
Crossref
Crossref
Emanuele Pontali, Giovanni Sotgiu, Lia D'Ambrosio, Rosella Centis & Giovanni Battista Migliori. (2016) Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. European Respiratory Journal 47:2, pages 394-402.
Crossref
Crossref